2. Signaling Pathways
  3. Transmembrane Glycoprotein

Transmembrane Glycoprotein

Transmembrane Glycoprotein

 

Transmembrane Glycoprotein Related Products (53):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-102022
    α-Galactosylceramide
    α-Galactosylceramide (α-GalCer) is a synthetic glycolipid with antitumorial and immunostimulatory. α-Galactosylceramide is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide plus CD1d binds the NKT cell TCR (T cell antigen receptor).
    α-Galactosylceramide
  • HY-P99208
    Lirilumab
    		Inhibitor
    Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
    Lirilumab
  • HY-147329
    RAGE 229
    		99.70%
    RAGE 229 is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE(ctRAGE) and Diaphanous-1(DIAPH1).
    RAGE 229
  • HY-P990673
    Vandortuzumab
    		Inhibitor 99.00%
    Vandortuzumab is a CHO-expressed humanized antibody targeting STEAP1. Vandortuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 148.74 kDa. The isotype control for Vandortuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Vandortuzumab
  • HY-128111
    ASN02563583
    		Activator 99.21%
    ASN02563583, a compound that regulates the activity of the GPR17 receptor, has a IC50 value of 0.64 nM in [35S]GTPγS binding assay. ASN02563583 can be used in the study of neurological diseases.
    ASN02563583
  • HY-P990859
    Anti-CD44 Antibody (Hermes-1)
    Anti-CD44 Antibody (Hermes-1) is a kind of rat IgG2a, κ chimeric antibody, targeting to human CD44. The recommend isotype control of Anti-CD44 Antibody (Hermes-1): Rat IgG2a kappa, Isotype Control (HY-P990679).
    Anti-CD44 Antibody (Hermes-1)
  • HY-P990792
    Anti-Mouse CD4 Antibody (GK1.5)
    Anti-Mouse CD4 Antibody (GK1.5) is a kind of rat IgG2b kappa in vivo mouse antibody, targeting to CD4. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682).
    Anti-Mouse CD4 Antibody (GK1.5)
  • HY-P990960
    Lucorafusp alfa
    HY-P990960 is an TIGIT-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Lucorafusp alfa
  • HY-P99329
    Vadastuximab
    		99.23%
    Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine.
    Vadastuximab
  • HY-113667
    ASN04885796
    		Activator 99.61%
    ASN04885796 (compound IV) is an GPR17 activator with an EC50 of 2.27 nM for GPR17 induced GTPγS binding. ASN04885796 has neuroprotective property and can be used for research of neurological diseases.
    ASN04885796
  • HY-P99958
    Vixtimotamab
    		Inhibitor
    Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML).
    Vixtimotamab
  • HY-P99266
    Zanolimumab
    		99.21%
    Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma.
    Zanolimumab
  • HY-P9983
    Lintuzumab
    		Inhibitor 98.09%
    Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR? and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice.
    Lintuzumab
  • HY-137605
    WSF1-IN-1
    		Inhibitor 99.91%
    WSF1-IN-1 (compound 136), an orally active WSF1 inhibitor, can be used in the study for WSF1 (Wolfram syndrome) related tumors, with IC50 values of 0.33 μM and >27 μM in HepG2 parental and HepG2 WFS1 KO cell lines, respectively.
    WSF1-IN-1
  • HY-N8102
    Echinocystic acid 28-O-β-D-glucoside
    		Inhibitor 99.11%
    Echinocystic acid 28-O-β-D-glucoside is a metabolite of Echinocystic acid by microbial oxidation and glucosidation. Echinocystic acid 28-O-β-D-glucoside is a tissue factor pathway inhibitor, with an IC50 of 10.61 nM.
    Echinocystic acid 28-O-β-D-glucoside
  • HY-W081348
    1-(4-Methoxyphenyl)-3-methyl-1H-pyrazol-5(4H)-one
    		99.54%
    1-(4-Methoxyphenyl)-3-methyl-1H-pyrazol-5(4H)-one (Compound 2) has antiprion activity in ScN2a and F3 cells with IC50 values of 13 nM and 25 nM, respectively.
    1-(4-Methoxyphenyl)-3-methyl-1H-pyrazol-5(4H)-one
  • HY-P99381
    XmAb 5592
    		Inhibitor 99.51%
    XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP).
    XmAb 5592
  • HY-P990607
    Indatuximab
    		Inhibitor 98.04%
    Indatuximab is a CHO-expressed, VHH-Fc (huIgG1) type chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 146.1 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
    Indatuximab
  • HY-157281
    Photolumazine III
    		99.96%
    Photolumazine III is a MHC class I related-1 molecule (MR1) antigen.
    Photolumazine III
  • HY-P990360
    Anti-CD9 Antibody
    		99.52%
    The Anti-CD9 Antibody is a humanized antibody expressed in CHO, targeting CD9. The Anti-CD9 Antibody is equipped with huIgG2 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 145.98 kDa. The isotype control for Anti-CD9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CD9 Antibody